Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia

Ph+ ALL is a poor-prognosis leukemia subtype driven by the BCR-ABL1 oncogene, either the p190- or the p210-BCR/ABL isoform in a 70:30 ratio. Tyrosine Kinase inhibitors (TKIs) are the drugs of choice in the therapy of Ph+ ALL. In combination with standard chemotherapy, TKIs have markedly improved the...

Descripción completa

Detalles Bibliográficos
Autores principales: Porazzi, Patrizia, De Dominici, Marco, Salvino, Joseph, Calabretta, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467343/
https://www.ncbi.nlm.nih.gov/pubmed/34573335
http://dx.doi.org/10.3390/genes12091355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467343/
https://www.ncbi.nlm.nih.gov/pubmed/34573335
http://dx.doi.org/10.3390/genes12091355

Ejemplares similares